Pharmaceutical News

RSS

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.

29 Oct 2013

Eisai supplies diethylcarbamazine citrate 100 mg tablets to WHO

Eisai Co., Ltd. announced today that it has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India to the World Health Organization in line with its commitment to help WHO in its global effort to eliminate lymphatic filariasis in targeted developing and emerging countries.

29 Oct 2013

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipo, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation), has received orphan drug designation from the US Food and Drug Administration.

29 Oct 2013

Study: Liposomal bupivacaine can provide longer-lasting nerve blocks

Can a new liposomal bupivacaine product provide long-lasting nerve block with a single injection? An initial study in humans shows promise-but also some "confusing results," reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Oct 2013

Beta-blockers increase risk of adverse cardiac event during noncardiac surgical procedure

A recent study shows that patients given beta-blockers may actually be at increased risk of having an adverse cardiac event during a noncardiac surgical procedure. Risk of irregular heartbeat and worsening of symptoms in patients with existing heart disease also seemed to increase, but to a lesser degree.

29 Oct 2013

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

People with a type of arthritis affecting the skin and joints respond significantly better to early, aggressive drug treatment compared to standard care, according to preliminary results presented by a University of Leeds lecturer to a major US conference.

29 Oct 2013

FDA approves use of Botox Cosmetic to treat crow's feet

The FDA approved the use of Botox Cosmetic to treat crow's feet on September 11th, 2013 after a trial of 833 adults showed the treatments reduced the appearance of wrinkles.

29 Oct 2013

High levels of omega-3 fatty acid consumption may lead to unintended health consequences

A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.

29 Oct 2013

African-American women less likely to benefit from HPV vaccines to prevent cervical cancer

Two subtypes of human papillomavirus prevented by vaccines are half as likely to be found in African-American women as in white women with precancerous cervical lesions, according to researchers at Duke Medicine.

29 Oct 2013

APR's Nexodyn receives European CE approval

APR announces the grant of the European CE approval of Nexodyn, a newly developed innovative product intended for use in a variety of wound conditions such as acute wounds, burns and advanced ulcers including venous and pressure ulcers and diabetic foot ulcers.

28 Oct 2013

Brief exposure to anabolic steroids may have long lasting performance-enhancing effects

Brief exposure to anabolic steroids may have long lasting, possibly permanent, performance-enhancing effects, shows a study published today [28 October] in The Journal of Physiology.

28 Oct 2013

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

DPP-4 inhibitors may reduce risk of autoimmune diseases

Dipeptidyl peptidase-4 inhibitors commonly used to control blood sugar levels in people with type 2 diabetes may also reduce the risk of autoimmune diseases in these patients, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Rituximab (Rituxan) — a drug commonly used rheumatoid arthritis, granulomatosis with polyangiitis (formerly Wegener's), and certain types of cancers — may be a safe and effective treatment for immunoglobulin G4-related disease (commonly called IgG4-RD), according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine.

25 Oct 2013

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

By the time bone cancer is diagnosed in a pet dog, it is often too late to save the animal's life. Instead, the goal of treatment is to keep the dog as comfortable and free of pain as possible for as long as possible.

25 Oct 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

Researchers publish comprehensive review of the benefits, risks of daily aspirin dosage

Researchers at Warwick Medical School have published the most comprehensive review of the benefits and risks of a daily dose of prophylactic aspirin and warn that greater understanding of side effects is needed.

25 Oct 2013

Pharmaceutical News

Serotonin 2C receptors induce fast-acting antidepressant effects in mice

Eisai supplies diethylcarbamazine citrate 100 mg tablets to WHO

Pharmalink's Busulipo receives FDA orphan drug designation

Study: Liposomal bupivacaine can provide longer-lasting nerve blocks

Beta-blockers increase risk of adverse cardiac event during noncardiac surgical procedure

Patients with psoriatic arthritis benefit from early aggressive drug treatment, says study

FDA approves use of Botox Cosmetic to treat crow's feet

High levels of omega-3 fatty acid consumption may lead to unintended health consequences

African-American women less likely to benefit from HPV vaccines to prevent cervical cancer

APR's Nexodyn receives European CE approval

Brief exposure to anabolic steroids may have long lasting performance-enhancing effects

Combination of three DMARDs more cost-effective in treating early rheumatoid arthritis

Apremilast drug shows promise for Behcet's ulcers

DPP-4 inhibitors may reduce risk of autoimmune diseases

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Rituximab drug may be safe, effective for immunoglobulin G4-related disease treatment

Scientists develop new drug to treat obstructive airway diseases

Research: Neurotoxin provides more relief from pain in dogs with bone cancer

Study finds persistent deficiency in new therapeutics for neglected diseases

Researchers publish comprehensive review of the benefits, risks of daily aspirin dosage

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News